CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
GSK1363089 (formerly XL880)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00725712
NCT00725712Phase 2Completed
CompareCT.gov

A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer

GlaxoSmithKline·interventional·Posted Jul 30, 2008·Updated Aug 24, 2017

In Brief

A Phase 2 clinical trial evaluating GSK1363089 (formerly XL880) for Neoplasms, Gastrointestinal Tract. Completed, enrolled 74 participants across 17 sites.

Detailed Summary

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Gastrointestinal Tract
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartMar 31, 2007
Primary CompletionNov 1, 2009
Study CompletionNov 30, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 17.9 years ago

Interventions

GSK1363089 (formerly XL880)drug

c-MET tyrosine kinase inhibitor